ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
ARCA biopharma, Inc. (ABIO)
US:NASDAQ Investor Relations:
arcabio.com/investors
Company Research
Source: GlobeNewswire
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We continue to be encouraged with the opportunities we see in our development pipeline compounds, rNAPc2 and Gencaro. With the ASPEN-COVID-19 Phase 2b trial of rNAPc2 expanding to South America, we look forward to completing the trial and we anticipate sharing the results in the fourth quarter. Given the rate of global vaccination and the continued emergence of variants, along with rNAPc2’s combination of anticoagulant, anti-inflammat
Show less
Read more
Impact Snapshot
Event Time:
ABIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABIO alerts
High impacting ARCA biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
ABIO
News
- ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- ARCA biopharma, Inc. (NASDAQ: ABIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- ARCA biopharma, Inc. (NASDAQ: ABIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANSS, HRT, CHX, ABIOPR Newswire
ABIO
Sec Filings
- 4/25/24 - Form 425
- 4/25/24 - Form 8-K
- 4/25/24 - Form 10-Q
- ABIO's page on the SEC website